These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38099145)

  • 21. Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study.
    Wang Y; Yu X
    Kidney Dis (Basel); 2024 Apr; 10(2):132-142. PubMed ID: 38659701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
    Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
    Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
    Jia L; Dong X; Yang J; Jia R; Zhang H
    Ann Transl Med; 2019 Dec; 7(23):720. PubMed ID: 32042736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S; Tanaka T; Nangaku M
    Rinsho Ketsueki; 2021; 62(5):371-377. PubMed ID: 34108317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular safety of current and emerging drugs to treat anaemia in chronic kidney disease: a safety review.
    Locatelli F; Paoletti E; Del Vecchio L
    Expert Opin Drug Saf; 2023; 22(12):1179-1191. PubMed ID: 38111209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Patients with Renal Anemia: A Meta-Analysis of Randomized Trials.
    Wen T; Zhang X; Wang Z; Zhou R
    Nephron; 2020; 144(11):572-582. PubMed ID: 32866960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term treatment of chronic kidney disease patients with anemia using hypoxia-inducible factor prolyl hydroxylase inhibitors: potential concerns.
    He J; Jia Z; Zhang A; Bai M
    Pediatr Nephrol; 2024 Jan; 39(1):37-48. PubMed ID: 37284874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in heart failure patients: A protocol for systematic review and meta-analysis.
    Fukuta H; Hagiwara H; Kamiya T
    PLoS One; 2022; 17(9):e0275311. PubMed ID: 36170343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Hypoxia-inducible factor-prolyl hydroxylase inhibitors: the "alternative" for EPO?].
    Rawee P; Eisenga MF
    Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updates on Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in the Treatment of Renal Anemia.
    Li J; Haase VH; Hao CM
    Kidney Dis (Basel); 2023 Jan; 9(1):1-11. PubMed ID: 36756084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors and Iron Metabolism.
    Ogawa C; Tsuchiya K; Maeda K
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y; Tanaka T; Nangaku M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):414-422. PubMed ID: 32452915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease.
    Johnson HN; Prasad-Reddy L
    Ann Pharmacother; 2024 Apr; ():10600280241241563. PubMed ID: 38616529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD).
    Noonan ML; Clinkenbeard EL; Ni P; Swallow EA; Tippen SP; Agoro R; Allen MR; White KE
    Physiol Rep; 2020 Jun; 8(11):e14434. PubMed ID: 32476270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Therapy for Anemia in Renal Transplantation Patients by Prior Erythropoiesis Stimulating Agent Use.
    Nakamura N; Aso S; Nakagawa C; Tachibana M; Fujikawa A; Tsubouchi K; Gunge N; Miyazaki T; Okabe Y; Matsuzaki H; Matsuoka H; Haga N
    Transplant Proc; 2023 May; 55(4):829-831. PubMed ID: 37105829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in Metabolomic Profiles Induced by Switching from an Erythropoiesis-Stimulating Agent to a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor in Hemodialysis Patients: A Pilot Study.
    Watanabe K; Sato E; Mishima E; Moriya S; Sakabe T; Sato A; Fujiwara M; Fujimaru T; Ito Y; Taki F; Nagahama M; Tanaka K; Kazama JJ; Nakayama M
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.